Combined use of extended-release niacin and atorvastatin： safety and effects on lipid modification

Background Cholesterol-lowering therapy with statins has been reported to reduce the morbidity and mortality of cardiovascular diseases. This study aimed to investigate the effects of combined application of extended-release niacin and atorvastatin on lipid profile modification and the risks of adverse events in patients with coronary artery disease. Methods Consecutive 108 patients with coronary artery disease and serum total cholesterol （TC） 〉 3.5 mmol/L were randomized into two groups： group A using atorvastatin and group B using extended-release niacin （niacin ER） and atorvastatin. Plasma lipid profile, glucose, and adverse events were assessed at the hospitalization, and 6 and 12 months after treatment. In addition, clinical cardiovascular events were evaluated after 12 months of treatment. Results The levels of TC, low density lipoprotein cholesterol （LDL-C） were significantly decreased （P 〈0.05） in groups A and B, but the levels of high density lipoprotein cholesterol （HDL-C） and ApoA increased by 29.36% and 40.81% respectively after 12 months of treatment in group B （P 〈0.01）. The medications were generally well tolerated in the two groups. No significant difference of adverse events was found between the two groups （group A： 3.2% vs group B 5.1%, P 〉0.05）. Conclusions Combined use of extended-release niacin with atorvastatin was superior to atorvastatin monotherapy alone in lipid profile regulation. Combination therapy with niacin ER and atorvastatin was well tolerated and safe in patients with coronary artery disease.

Modification of ubiquitin C-terminal hydrolase L1 by reactive lipid species: role in neural regeneration and diseases of aging

Role of ubiquitin C-terminal hydrolase L1（UCHL1）in brain function：Ubiquitin is used by a variety of cellular systems to tag proteins for transport to various organelles.There are a number of enzymes in the ubiquitin-proteasome pathway（UPP）that tag abnormally folded proteins with ubiquitin for transport to the proteasome for degradation.

Introduction to the International Symposium on Lipid Science and Health and research progress in lipid science and health

The International Symposium on Lipid Science and Health(ISLSH),which was organized annually by Oil Crops Research Institute of Chinese Academy of Agricultural Sciences(OCRI-CAAS)since 2016,has gained a strong reputation and attracted hundreds of delegates from around the world for discussion of lipid research trends and advances every year,to promote research and academic exchanges in the fields of lipid science and health.The 5th International Symposium on lipid Science and Health was successfully held in Wuhan,China,from October 23rd to 25th,2020,to celebrate the 60th anniversary of OCRI-CAAS.The two-day symposium gathered wellknown experts specialized in lipid science to share the current state of lipid research with emphasis on aspects covering:(1)lipid profiling and characterization,(2)lipid preparation and modification,(3)lipid improvement and regulation,and(4)lipid nutrition and health.The symposium was conducted by a combination of on-site and network meeting.More than 250 distinguished delegates from academia and industry participated in the on-site multidisciplinary meeting,and thousands of scholars attended the virtual event.This paper is as a record of the symposium proceedings and a brief summary of the advances and trends in 4 aspects of lipid science and health.

Sub-nanosized vanadate hybrid clusters maintain glucose homeostasis and restore treatment response in inflammatory disease in obese mice

Obesity is closely related with insulin resistance and chronic inflammation.Here,we report that unsaturated lipid-modified polyoxovanadates(ULPOVs)can restrict weight gain of diet-induced obese mice and improve their glycemic control and obesity-associated inflammation.Oral administration of the sub-nanosized ULPOVs at a low dosage for 7 weeks reduces the body weight and almost normalizes the blood glucose levels of obese mice fed on a high-fat diet.ULPOV treatment increases the activity of the nuclear receptor peroxisome proliferator-activated receptorγ(PPARγ)and reduces intestinal caloric intake,which may be the main reason for blood sugar and body weight control.In addition to insulin-sensitizing,PPARγactivation induced by ULPOV treatment in obese mice with atopic dermatitis(AD)promotes the type 2 T helper(TH_(2))cell selective responses and therapeutic effects on immune dysregulation caused by obesity.These data suggest sub-nanosized polyoxovanadate clusters as a class of potential candidates to relieve symptoms accompanied by diet-induced obesity.